サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1654730

抗老化治療薬の世界市場：2025年～2033年

Global Anti-senescence Therapeutics Market - 2025-2033

出版日
ページ情報
英文 176 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.90円
抗老化治療薬の世界市場：2025年～2033年
出版日: 2025年02月13日
発行: DataM Intelligence
ページ情報: 英文 176 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の抗老化治療薬市場は、2024年に309億6,000万米ドルに達し、2033年までには533億9,000万米ドルに達すると予測され、予測期間中の2025年から2033年のCAGRは6.7%で成長します。

抗老化治療薬は、加齢に伴う生物学的プロセス、特に細胞老化の遅延や回復を目的とした医療介入のカテゴリーを指します。細胞老化は、細胞機能が徐々に低下し、アポトーシス（プログラムされた細胞死）に対する抵抗性が高まることを特徴とし、加齢に関連する疾患の一因となります。これらの治療法の目的は、老化の根本的なメカニズムを標的とすることによって、長寿を増進し、健康でいられる期間を改善することです。

細胞老化は、細胞分裂が永久に停止することで特徴づけられるプロセスであり、DNA損傷、酸化ストレス、テロメア短縮などの要因によって引き起こされることが多いです。老化細胞は炎症性因子を分泌し、組織機能を破壊し、老化を促進します。これらの要因が、世界の抗老化治療薬市場拡大の原動力となっています。

市場力学：

促進要因と抑制要因

慢性疾患の増加と高齢化

世界の抗老化治療薬市場の需要は、複数の要因によって牽引されています。心血管疾患、神経変性疾患、がん、代謝性疾患など、加齢に関連する慢性疾患の有病率の増加は、抗老化治療薬市場の成長を促進する主要因です。

世界人口の高齢化が進むにつれて、これらの加齢関連疾患の発生は増加します。WHOが2022年10月に発表したデータによると、65歳以上の高齢者数は2050年までに倍増し、約15億人になると予測されており、高齢化人口の増加と加齢関連疾患の増加が抗老化治療薬市場の需要を押し上げると思われます。予防ヘルスケアの重要性に関する高齢化社会の意識の高まりは、長寿と加齢関連疾患の予防を目的としたサプリメント、医薬品、生活習慣の改善に対する需要を促進すると思われます。

さらに、M&Aなどの主要企業の戦略や、投資などの政府の取り組みが、この市場の成長を促進すると思われます。例えば、2024年1月、Healthy Extracts Inc.は、数十億米ドル規模の栄養補助食品市場内の高成長分野をターゲットとした植物ベースの栄養補助食品の買収、開発、特許取得、マーケティング、流通に特化したプラットフォームです。同社は、皮膚の活力を促進し、動脈の柔軟性を高め、細胞や関節の健康をサポートすることを目的とした独自の製剤であるロンゲビティ・アンチエイジングを発表しました。これらすべての要因が、世界の抗老化治療薬市場に需要をもたらしています。

さらに、研究開発の進歩に対する需要の高まりも、世界の抗老化治療薬市場の拡大に寄与しています。

限られた製品承認

抗老化治療薬の世界市場では、製品承認が限られているため、市場の成長と革新の妨げとなる重大な課題があります。アンチエイジング・抗老化療法の規制状況は複雑で、進化しています。米国食品医薬品局（FDA）などの規制機関は、新しい治療法の承認を与える前に、安全性と有効性を実証する広範な臨床データを要求します。

潜在的な抗老化療法の多くはまだ研究開発の初期段階にあり、後期臨床試験まで進んでいるものはほとんどありません。例えば、老化細胞を標的にする抗老化薬への関心は高まっていますが、これらの化合物の多くは、承認を裏付ける十分な臨床試験データがありません。

CitelineのBiomedtracker予測によると、FDAは2025年に様々な治療領域で約70件の承認と表示拡大を行うと予想されていますが、老化や老化現象を具体的にターゲットにした数はまだ不明です。2025年初頭の時点で、複数の有望候補がデータ不足や安全性の懸念からFDAから審査完了通知（CRL）を受け取っています。このように、上記の要因が世界の抗老化治療薬市場の潜在的成長を制限している可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 慢性疾患の増加と人口の高齢化
    • 抑制要因
      • 限定製品承認
    • 機会
    • 影響分析

第5章 戦略的洞察と業界展望

  • 市場のリーダーと先駆者
    • 新たな先駆者と著名企業
    • 最大の売上を誇るブランドを確立したリーダー
    • 確立された製品を持つ市場リーダー
  • CXOの視点
  • 最新の開発とブレークスルー
  • ケーススタディ/進行中の調査
  • 規制と償還の情勢
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大のための推奨戦略
  • シナリオ分析ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格市場力学
  • キーオピニオンリーダー

第6章 治療タイプ別

  • 栄養補助食品
    • NMN（ニコチンアミドモノヌクレオチド）
    • PQQ（ピロロキノリンキノン）
    • アピゲニン
    • L-トリプトファン
    • その他
  • 老化防止薬
  • その他

第7章 用途別

  • 心血管疾患
  • がん
  • その他

第8章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第9章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州地域
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋
  • 中東・アフリカ

第10章 競合情勢

  • 競合シナリオ
  • 市況・シェア分析
  • M&A分析

第11章 企業プロファイル

  • Decode Age
    • 会社概要
    • 製品ポートフォリオ
      • 製品説明
      • 製品の主要業績評価指標（KPI）
      • 過去および予測の製品販売
      • 製品販売量
    • 財務概要
      • 会社の収益
      • 地域別収益分配
      • 収益予測
    • 主な発展
      • 合併と買収
      • 主な製品開発活動
      • 規制当局の承認等
    • SWOT分析
  • Zeroharm
  • Gataca
  • Longevity By Nature
  • ProHealth, Inc.
  • Xandro Lab.
  • NanoSPACE
  • AgeX Therapeutics, Inc.
  • T.A. SCIENCES
  • Elysium Health, Inc.
  • Bristol-Myers Squibb Company

第12章 付録

目次
Product Code: PH8673

The global anti-senescence therapeutics market reached US$ 30.96 billion in 2024 and is expected to reach US$ 53.39 billion by 2033, growing at a CAGR of 6.7 % during the forecast period 2025-2033.

Anti-senescence therapeutics refer to a category of medical interventions aimed at delaying or reversing the biological processes associated with aging, particularly cellular senescence. Cellular senescence is characterized by the gradual deterioration of cellular function and increased resistance to apoptosis (programmed cell death), which contributes to age-related diseases. The goal of these therapies is to enhance longevity and improve health span the period of life spent in good health by targeting the underlying mechanisms of aging.

Cellular senescence this process is marked by a permanent halt in cell division, often triggered by factors such as DNA damage, oxidative stress, or telomere shortening. Senescent cells can secrete inflammatory factors that disrupt tissue function and promote further aging. These factors have driven the global anti-senescence therapeutics market expansion.

Market Dynamics: Drivers & Restraints

Rising prevalence of chronic diseases and aging population

The demand for the global anti-senescence therapeutics market is driven by multiple factors. The increasing prevalence of chronic diseases linked to aging, including cardiovascular diseases, neurodegenerative disorders, cancer, and metabolic disorders, is a major factor propelling the growth of the anti-senescence therapeutics market.

As the global population continues to age, the occurrence of these age-related conditions rises. As per WHO data in October 2022, the increase in the number of individuals aged 65 and older, which is expected to double by 2050 to around 1.5 billion, the rising number of aging population and age-related diseases that would propel will the demand for the anti-senescence therapeutics market. The growing awareness among the aging population regarding the significance of preventive healthcare will drive the demand for supplements, medications, and lifestyle changes designed to enhance longevity and avert age-related illnesses.

Moreover, key players' strategies such as mergers & acquisitions, and government initiatives such as investments would propel this market growth. For instance, in January 2024, Healthy Extracts Inc. is a platform dedicated to acquiring, developing, patenting, marketing, and distributing plant-based nutraceuticals targeting high-growth sectors within the multibillion-dollar nutraceuticals market. The company has introduced LONGEVITY Anti-Aging, a proprietary formulation aimed at promoting skin vitality, enhancing arterial flexibility, and supporting cellular and joint health. All these factors demand the global anti-senescence therapeutics market.

Moreover, the rising demand for the advancements in research and development contributes to the global anti-senescence therapeutics market expansion.

Limited Product Approvals

The limited product approvals in the global anti-senescence therapeutics market poses significant challenges that can hinder market growth and innovation. The regulatory landscape for anti-aging and anti-senescence therapies is complex and evolving. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA), require extensive clinical data demonstrating safety and efficacy before granting approval for new therapies.

Many potential anti-senescence therapies are still in the early stages of research and development, with few progressing to late-stage clinical trials. For instance, while there is a growing interest in senolytic drugs that target senescent cells, many of these compounds lack sufficient clinical trial data to support their approval.

According to Citeline's Biomedtracker projections, the FDA is expected to deliver around 70 approvals and label expansions across various therapeutic areas in 2025; however, the number specifically targeting aging or senescence remains uncertain.As of early 2025, multiple promising candidates have received Complete Response Letters (CRLs) from the FDA due to insufficient data or safety concerns. Thus, the above factors could be limiting the global anti-senescence therapeutics market's potential growth.

Segment Analysis

The global anti-senescence therapeutics market is segmented based on treatment type, application, distribution channel, and region.

Treatment Type:

The senolytic drugs segment is expected to dominate the global anti-senescence therapeutics market share

The senolytic drugs segment holds a major portion of the global anti-senescence therapeutics market share and is expected to continue to hold a significant portion of the global anti-senescence therapeutics market share during the forecast period. Senolytic drugs are a category of therapeutic agents designed to specifically target and eliminate senescent cells cells that have stopped dividing but remain metabolically active and contribute to aging and various age-related diseases. By removing these senescent cells, senolytic drugs aim to enhance healthspan and potentially extend lifespan.

Natural senolytics compounds are derived from natural sources like plants. Notable examples include quercetin, fisetin, and curcumin. Due to their availability and perceived safety, natural senolytics are expected to hold a significant portion of the market. These are chemically engineered compounds, such as navitoclax, dasatinib, and FOXO4-DRI. Synthetic senolytics are projected to see considerable growth, driven by advances in biotechnology and pharmaceutical development.

Senolytic drugs may play a role in treating age-related cardiovascular conditions like atherosclerosis and hypertension by reducing the inflammation and vascular stiffening caused by senescent cells in blood vessels. Neurological disorders like Alzheimer's and Parkinson's, linked to the accumulation of senescent cells in the brain and nervous system, may benefit from senolytic therapies.

Osteoarthritis these drugs could be used to manage osteoarthritis by targeting inflammation and tissue degeneration caused by senescent cells in joint tissues. In cancer senolytic drugs may help improve cancer treatments by eliminating therapy-induced senescent cells, which contribute to cancer recurrence and resistance, thus potentially enhancing treatment outcomes and reducing side effects.

Furthermore, key players in the industry innovative launches that would drive this global anti-senescence therapeutics market growth. For instance, in January 2023, Seragon Biosciences, Inc. launched RESTORIN, an advanced nutraceutical designed to promote healthy aging. This product incorporates a variety of patented technologies developed in collaboration with esteemed institutions such as Harvard University, Mayo Clinic, and Scripps Research.

RESTORIN features a unique blend of senolytic agents, NAD+ precursors, and sirtuin-activating compounds (STACs). Senolytics are specialized molecules that target and eliminate senescent cells-those that accelerate aging and contribute to the decline of organ function. NAD+ is a crucial coenzyme that supports cellular energy production, DNA repair, and overall cellular health, serving as the essential fuel for sirtuins, proteins that play a key role in longevity and maintaining cellular vitality. These factors have solidified the segment's position in the global anti-senescence therapeutics market.

Geographical Analysis

North America is expected to hold a significant position in the global anti-senescence therapeutics market share

North America holds a substantial position in the global anti-senescence therapeutics market and is expected to hold most of the market share. North America's aging population is expanding significantly. By 2050, nearly 27% of the population will be aged 65 or older, leading to a rise in age-related diseases. This demographic shift is increasing the demand for anti-senescence therapies aimed at improving health and extending life expectancy.

This region remains at the forefront of biotechnological breakthroughs, particularly in gene therapy, stem cell research, and the development of senolytic drugs. These innovations are opening up new possibilities for therapies that address the biological mechanisms of aging, driving the growth of the market. Healthcare spending in North America continues to increase, with the World Health Organization reporting a global health expenditure of $9.8 trillion in 2021. This growth includes increased investment in treatments for age-related diseases, providing critical financial support for the development of anti-senescence therapeutics.

There is an increasing consumer interest in anti-aging products and therapies, driven by greater awareness of aging-related health concerns. As individuals seek ways to extend their health span and prevent age-related conditions, the market for anti-senescence therapeutics is expanding. Together, these factors position North America as a leader in the research, development, and commercialization of therapies targeting aging, improving the quality of life for an aging population.

Furthermore, in this region a major number of key players presence, well-advanced healthcare infrastructure and key players strategies such as parentships & collaborations that would drive this global anti-senescence therapeutics market growth. For instance, in July 2024, in Texas MDB Capital Holdings, LLC announced a significant collaboration with the Mayo Clinic to develop a small molecule anti-senescence platform.

This partnership is formalized through a patent and know-how agreement and is aimed at advancing research in the fields of longevity and the prevention of age-related diseases. Thus, the above factors are consolidating the region's position as a dominant force in the global anti-senescence therapeutics market.

Asia Pacific is growing at the fastest pace in the global anti-senescence therapeutics market share

Asia Pacific holds the fastest pace in the global anti-senescence therapeutics market and is expected to hold most of the market share. The Asia-Pacific region is seeing a significant rise in its elderly population. By 2050, it is expected that approximately 27% of North America's population will be aged 65 or older. This demographic shift is contributing to an increased prevalence of age-related diseases, which in turn is driving the demand for anti-senescence therapies focused on improving health and extending lifespan.

This region is a hub for cutting-edge biotechnological advancements, including gene therapy, stem cell research, and the development of senolytic drugs. These innovations are opening up new avenues for therapies that specifically target the biological mechanisms of aging, thus accelerating market growth. Together, these factors are driving the robust expansion of the anti-senescence therapeutics market in the Asia-Pacific region, positioning it as a leader in the development and adoption of therapies aimed at combating aging and improving overall health.

For instance, in August 2024, Japanese scientists making significant strides in regenerative gene transfer for anti-aging treatments. This cutting-edge technique utilizes gene transfer to repair and regenerate cells and tissues, potentially reversing age-related damage at the cellular level. By specifically targeting senescent cells those that accelerate aging and contribute to organ degeneration this regenerative approach holds the potential to slow or even reverse the aging process.

This breakthrough could transform anti-aging therapies, opening new pathways for treatments that not only address aging symptoms but also work at the genetic and cellular level to rejuvenate tissues, boosting longevity and enhancing overall well-being. Thus, the above factors are consolidating the region's position as the fastest-growing force in the global anti-senescence therapeutics market.

Competitive Landscape

The major global players in the anti-senescence therapeutics market include Decode Age, Zeroharm, Gataca, Longevity By Nature, ProHealth, Inc., Xandro Lab., NanoSPACE, AgeX Therapeutics, Inc., T.A. SCIENCES, Elysium Health, Inc., and Bristol-Myers Squibb Company among others.

Key Developments

  • In September 2024, Bayer is making significant advancements with its innovative Age Factor ecosystem. This ecosystem integrates three essential elements: a scientifically formulated dietary supplement, an advanced wellness companion app, and a saliva-based biological age test developed by Chronomics.
  • In June 2024, One A Day, launched a new product called One A Day Age Factor Cell Defense. This dietary supplement is designed to support cellular health, which is where the aging process begins.
  • In November 2023, Saudi Arabia's Hevolution Foundation, a prominent initiative dedicated to addressing aging, announced a substantial investment of $40 million in research grants following the inaugural Global Healthspan Summit. This significant funding aims to catalyze groundbreaking discoveries in aging science.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global anti-senescence therapeutics market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Treatment Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Prevalence of Chronic Diseases and Aging Population
    • 4.1.2. Restraints
      • 4.1.2.1. Limited Product Approvals
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Strategic Insights and Industry Outlook

  • 5.1. Market Leaders and Pioneers
    • 5.1.1. Emerging Pioneers and Prominent Players
    • 5.1.2. Established leaders with largest selling Brand
    • 5.1.3. Market leaders with established Product
  • 5.2. CXO Perspectives
  • 5.3. Latest Developments and Breakthroughs
  • 5.4. Case Studies/Ongoing Research
  • 5.5. Regulatory and Reimbursement Landscape
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa
  • 5.6. Porter's Five Force Analysis
  • 5.7. Supply Chain Analysis
  • 5.8. Patent Analysis
  • 5.9. SWOT Analysis
  • 5.10. Unmet Needs and Gaps
  • 5.11. Recommended Strategies for Market Entry and Expansion
  • 5.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 5.13. Pricing Analysis and Price Dynamics
  • 5.14. Key Opinion Leaders

6. By Treatment Type

  • 6.1. Introduction
    • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 6.1.2. Market Attractiveness Index, By Treatment Type
  • 6.2. Dietary Supplements*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 6.2.3. NMN (Nicotinamide Mononucleotide)
    • 6.2.4. PQQ (Pyrroloquinoline Quinone)
    • 6.2.5. Apigenin
    • 6.2.6. L-Tryptophan
    • 6.2.7. Others
  • 6.3. Senolytic Drugs
  • 6.4. Others

7. By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 7.1.2. Market Attractiveness Index, By Application
  • 7.2. Cardiovascular Diseases*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Cancer
  • 7.4. Others

8. By Distribution Channel

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 8.1.2. Market Attractiveness Index, By Distribution Channel
  • 8.2. Hospital Pharmacies*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Retail Pharmacies
  • 8.4. Online Pharmacies

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Spain
      • 9.3.6.5. Italy
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. South Korea
      • 9.5.6.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Decode Age*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio
      • 11.1.2.1. Product Description
      • 11.1.2.2. Product Key Performance Indicators (KPIs)
      • 11.1.2.3. Historic and Forecasted Product Sales
      • 11.1.2.4. Product Sales Volume
    • 11.1.3. Financial Overview
      • 11.1.3.1. Company Revenue's
      • 11.1.3.2. Geographical Revenue Shares
      • 11.1.3.3. Revenue Forecasts
    • 11.1.4. Key Developments
      • 11.1.4.1. Mergers & Acquisitions
      • 11.1.4.2. Key Product Development Activities
      • 11.1.4.3. Regulatory Approvals etc.
    • 11.1.5. SWOT Analysis
  • 11.2. Zeroharm
  • 11.3. Gataca
  • 11.4. Longevity By Nature
  • 11.5. ProHealth, Inc.
  • 11.6. Xandro Lab.
  • 11.7. NanoSPACE
  • 11.8. AgeX Therapeutics, Inc.
  • 11.9. T.A. SCIENCES
  • 11.10. Elysium Health, Inc.
  • 11.11. Bristol-Myers Squibb Company

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us